Fig. 2 | Scientific Reports

Fig. 2

From: Association between glucagon-like peptide-1 receptor agonist therapy and respiratory illness in patients with type 2 diabetes: a retrospective observational cohort study

Fig. 2

Subgroup analysis for lung cancer. Lung cancer risk in GLP-1 RA users versus DPP4i users. The vertical line indicates an HR of 1.00. A lower limit of the 95% CI greater than 1.00 indicates a significantly higher risk. GLP1-RA glucagon-like peptide-1 receptor agonist, DPP4i dipeptidyl peptidase-4 inhibitor, HR hazard ratio, CI confidence interval, BMI body mass index, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin.

Back to article page